Reshaping the HIV treatment and prevention landscape
Key growth drivers: opportunities and investment priorities
Illustrative
Vaccines
Specialty Medicines
General Medicines
More than
5% CAGR
+ Shingrix
+ Meningitis
+ Dovato
+ Cabenuva
+ Zejula
+ Blenrep
+ Jemperli*
+ Benlysta
+ Nucala
+ RSV
+ Men ABCWY
+ Cab PrEP
+ Zejula
+ Blenrep
+ Jemperli
+ depemokimab ('294)
+ otilimab
+ daprodustat
2021
+ Trelegy
+ gepotidacin
Marketed assets
Late-stage Pipeline
2026
Vaccines high single digit CAGR 2021-26
Shingrix - double revenues in 5 years
gsk
Meningitis - aim to double revenues in 10 years
dolutegravir
RSV - £Multi-billion peak year sales
conotidacin
↑ LAMIV CONTIDOS
Flu - new strategy to double revenues in 10 years
LOD
+ base decine
Growu anivers
2031
Cany pipelineT DD
Note: Bars are not at scale. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of
Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and
include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.
Assets highlighted reflect major contributions to growth in period shown.
*Tesaro asset
63View entire presentation